Maze Therapeutics (MAZE) Gross Profit (2025 - 2026)

Maze Therapeutics (MAZE) reported Gross Profit of $18.2 million for Q1 2026, up 1633.95% on a YoY basis from $1.1 million in Q1 2025, and up 1633.95% sequentially from -$1.2 million in Q1 2025.

Maze Therapeutics (MAZE) Gross Profit (2025 - 2026) Analysis & Trends

Maze Therapeutics (MAZE) has 2 years of Gross Profit data on file, last reported at $18.2 million in Q1 2026.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 67,072.09 Bn 67,072.09 Bn -
2 Nanobiotix 1,894.61 Bn 1,894.55 Bn -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn -
4 BeOne Medicines 471.64 Bn 466.85 Bn 1.35 Bn
5 Vertex Pharmaceuticals 121.72 Bn 114.47 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 68.28 Bn 59.52 Bn 3.31 Bn
7 Belite Bio 61.40 Bn 61.40 Bn -
8 Argenx Se 56.94 Bn 56.94 Bn 1.18 Bn
9 Revolution Medicines 37.37 Bn 37.37 Bn -
10 Maze Therapeutics 1.49 Bn 1.49 Bn 18.21 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 18.21 Mn
Mar 31, 2026 18.21 Mn
Mar 31, 2025 -1.19 Mn
Mar 31, 2025 -1.19 Mn